PPT-Oral Antiplatelet Therapy in ACS

Oral Antiplatelet Therapy in ACS PLATO Primary Efficacy Outcome by Geography US vs NonUS CURE Incidence of Major Bleeding According to Aspirin Dose of Patients CHARISMA Bleeding End Points by Baseline Daily Aspirin Dose. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . Dr Darren Reed FY1. Scenario 1. 58 year old man. 30 minute history of severe chest pain, 10/10, radiating to jaw, not relieved by anything, associated with sweating and nausea. Known angina.. What investigations would you like?. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Insights. Jose Rodas . jorodas@microsoft.com. Premier Field Engineer. Microsoft. Agenda . System Center Overview. SCOM . ACS . Architecture. SCOM . ACS . Scenarios. Operations . Management . Suite. OMS Architecture. Mary Moore 2012 Chair of CTA. Early Years. An . adhoc. committee led by William G. Young was charged to explore all aspects of technician relationships to the ACS. “Semi-professional” was the name most used concerning technicians. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . People with diabetes have a 2 to 4 fold higher risk of dying from cardiovascular disease. People with diabetes have a complex procoagulant state, which contributes to the increased risk of atheroscler 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. CrCl. : creatinine clearance, CTO: chronic total occlusion, DAPT: dual antiplatelet therapy, DOAC: direct oral anticoagulant, . eDAN. : electronic discharge advice notification, GFR: glomerular filtration rate, HF: heart failure, INR: international normalised ratio, LHP: Leeds Health Pathways, LTHT: Leeds Teaching Hospitals NHS Trust, LV: left ventricular, MACE: major adverse cardiovascular event, MI: myocardial infarction, NICE: National Institute for Health and Care Excellence, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction, OD: once daily, PAD: peripheral arterial disease, P2Y12: platelet receptor for adenosine diphosphate PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SPC: summary of product characteristics, TIA: transient ischaemic attack..